{"name":"Dompé Farmaceutici S.p.A","slug":"domp-farmaceutici-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"DFL24498","genericName":"DFL24498","slug":"dfl24498","indication":"Other","status":"phase_3"},{"name":"KSL 40 mg","genericName":"KSL 40 mg","slug":"ksl-40-mg","indication":"Other","status":"phase_1"},{"name":"Repertaxin","genericName":"Repertaxin","slug":"repertaxin","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Ketoprofen Lysine Salt","genericName":"Ketoprofen Lysine Salt","slug":"ketoprofen-lysine-salt","indication":"Acute pain management","status":"marketed"},{"name":"OXERVATE® 0.002%","genericName":"OXERVATE® 0.002%","slug":"oxervate-0-002","indication":"Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage)","status":"marketed"},{"name":"Oxervate","genericName":"Oxervate","slug":"oxervate","indication":"Neurotrophic keratitis","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"OKITASK®","genericName":"OKITASK®","slug":"okitask","indication":"Dry eye disease (moderate to severe)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Libexin®","genericName":"Libexin®","slug":"libexin","indication":"Dry cough and unproductive cough in various respiratory conditions","status":"phase_3"}]}],"pipeline":[{"name":"DFL24498","genericName":"DFL24498","slug":"dfl24498","phase":"phase_3","mechanism":"DFL24498 is a tyrosine kinase inhibitor targeting specific oncogenic pathways in cancer cells.","indications":[],"catalyst":""},{"name":"OKITASK®","genericName":"OKITASK®","slug":"okitask","phase":"phase_3","mechanism":"OKITASK is a topical ophthalmic agent designed to promote corneal healing and reduce inflammation in dry eye disease.","indications":["Dry eye disease (moderate to severe)"],"catalyst":""},{"name":"KSL 40 mg","genericName":"KSL 40 mg","slug":"ksl-40-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ketoprofen Lysine Salt","genericName":"Ketoprofen Lysine Salt","slug":"ketoprofen-lysine-salt","phase":"marketed","mechanism":"Ketoprofen lysine salt is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antipyretic effects.","indications":["Acute pain management","Postoperative pain","Migraine headache","Musculoskeletal pain and inflammation"],"catalyst":""},{"name":"Libexin®","genericName":"Libexin®","slug":"libexin","phase":"phase_3","mechanism":"Libexin is a non-narcotic antitussive agent that suppresses cough by acting as a local anesthetic on the respiratory mucosa and reducing airway irritation.","indications":["Dry cough and unproductive cough in various respiratory conditions"],"catalyst":""},{"name":"OXERVATE® 0.002%","genericName":"OXERVATE® 0.002%","slug":"oxervate-0-002","phase":"marketed","mechanism":"OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy.","indications":["Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage)"],"catalyst":""},{"name":"Oxervate","genericName":"Oxervate","slug":"oxervate","phase":"marketed","mechanism":"High affinity nerve growth factor receptor, Tumor necrosis factor receptor superfamily member 16","indications":["Neurotrophic keratitis"],"catalyst":""},{"name":"Repertaxin","genericName":"Repertaxin","slug":"repertaxin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNTkdScVptYklQRW1ZTXdrb29sRFVZS3l1N2xRWlFmR3JXWXM5Y2xnd3NjdFVJTlc4emVxcXlBYTIwRnFPVHJJbWI0X3VHQ1FFVGVXQkJIU3dDVTM5Uy1RVHljZDd2T0MxSnZBZDItWVhnQS1IeDAxUGF5Q09uNmhJOHRpR3pEcVA5U1dxVEhOYmdEczJmbVk5andHZ2tfOGh6cjMyYlB1cklnaEc2UTVmRWJuZGpObG84dHZsbDZzSTJsa21EM24zSWhyRThFeUd4TVZCMHluLVhVNmZrSE9VczNMNXd5X0d3V3BUQzBORzI?oc=5","date":"2026-02-10","type":"pipeline","source":"BioSpace","summary":"OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - BioSpace","headline":"OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Office","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQU1BLRUlTU0h0ZjNqbEFoRXE2SVJwUmZPUF9IMDg0RkllSmtKYVU4bnlMNEszSmdoWTlRN1JfVEtJMV9CQ2s1WGNwa3JvZXFSbHFpOUlzVjdvNTdfM1FRYWZWelFPd3NscUk5RjFHLTI5QjNGNE5Zblc3ek0xVVNLZXBrZVEzVExhdmt0TjY0QzNGMUs5R2lVeldpOE5rNVo5cjdQdHQ1aGlKUDh5djZGMHN0cW90ZmFUdTZwT0xyQmRFSUg5SC1yQjd3?oc=5","date":"2026-02-10","type":"pipeline","source":"Investing.com","summary":"OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program - Investing.com","headline":"OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNZE5QRVctV3BDdGZVVUxhVnkyTzRTY3Y2VnlaZEd0QVI0Y0laemRCTEttWEk2ZlNSWWhzeDViYV83MWg4NllLNFBTMHVySjR4aUZFTXZCQzlaa1hWcndYZWFjWFVzZHlQVzRhQnE4Nk5LNTZCZ2lQRFhfTXZURm5EQktiYUM1NGNTRzllcXJCSmxrdXVveHFDRlpUX1I0em1FbDhSalVJTmhtZzJCSWZfUXNvMW1yRVhxSFNnemlmc011bzQwbXJsVjExX2xmQUlhYzg1MWZNalBnSWtoWDlGRF8xVWNWN0xSdU43MEFXbkhTcGZIRzBmMlROOXlpcU5xWE16NGxR?oc=5","date":"2026-02-10","type":"pipeline","source":"ChartMill","summary":"OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - ChartMill","headline":"OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Office","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPa3FoaVRVeXB3TVplNHVMak9kejI3UnJwQjk4dmlRb1BYVFZVU215THJWNTV1dDRuTERqWUxuQXR0UnVCSFZCbWI1V0ZVM3F4V0N6VGdjSWdHTld2Q1ZHWlVTay1wY1gxR1djUVFZMFZjVFhlalF5R1NtMWtRdE1zbWRRajJYd0NwUzVmZHZkdVJFTUFsZGZFMFZpbmIwQWdrV3l1Sjh1cGI0TlJoRF9NdVFjWXdGeTh3Z3ZaUTAzd2FPa3NnY3dVVW5WX0lLU01GbHg2NGRvSldpV0tFWjloMmhQd2R5UTRn?oc=5","date":"2025-10-16","type":"regulatory","source":"businesswire.com","summary":"Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program - businesswire.com","headline":"Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNZjVyUVRCNTZDcUxOYlNzd1dRSWZrUE1Qdlh1cEVNY2VHT0c0YU93U1ZuVnpCbzBlMDBkcUxGeHlFbktQbmhaQmpLOGF4bm92cDUxbHpTLUtlbzJ2amVnVy1ieXlsWElUcDRWQ0pYc1Q1N2c1R3hzS1lGcTM4R3dIV1hyTS1Ma0JCRlc5MGduX3V0REYxOVN3QmUwSVFReUVVX3VaUUV3SUJsTGlZTzYtZmFua0NIUnprUmp1V1N0amtUOHNzMTZPbEdQQkhpZ3NnYVI3cENlY25CcXktR3dmaFR0aGIzUExRaE95WmYwRzk1b0kzenNaLWVRMVk5Zw?oc=5","date":"2025-02-27","type":"pipeline","source":"GlobeNewswire","summary":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight - GlobeNewswire","headline":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQVFFULWNXQ3ZuTWtPR2JqR21wWkdKN0ozSExkNHJ5T2FZMWZMN2lkaVQ2S1JJTnhaeTd2Z0gwUGp0aDNweEtQLVV2TzhUTC1zVXRVeVVuM3FPQ2xiYmRxenphQ3B0MnE1cmFLS1hwTkxHTms5NmtxcU40aEdhWENhZ1R1X2hvenZMb0hYeWNVbzg0dzRTbi1JclZpMnpGR3h4Vk5LM1FpdzAyWmNVblZyRFRlUUlwc1psTlhtTzR0ZFQ1YW1SNENDSi1ZclB3ZHBybVBib0JEb25wdEJWQ1VzMVBRWQ?oc=5","date":"2025-01-07","type":"pipeline","source":"prnewswire.com","summary":"Tarsier Pharma Appoints Ashley Kline as Chief Commercial Officer, Expanding Its U.S. Presence - prnewswire.com","headline":"Tarsier Pharma Appoints Ashley Kline as Chief Commercial Officer, Expanding Its U.S. Presence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQTTFOMUVnQnRONkZ3NExua1ppTFk3TE0tZzAtWEl3ZXlKMmNuYzNoQ2ZGRjZVZU9HdE1LQmhWakZmTTFnWm42ajNUNDlvSV9DWVRDdGdxY0ZPRFNQY1dUbHpqQ2trZW95SmNfTk9kMXFGZnJiNEloa0Yzeno0YUttRnk0U3p1QWhnYkpBNG01eDdPVzNqTXd2OXVIcGpCekNVSVdSZXVvczNjelVfbGhSYkF4S2lqel90ME43MkxObVNjSW9md0wxS3ZPaXFMM0dZQmpXZW1WcnBHS1JzakdsYQ?oc=5","date":"2024-09-05","type":"pipeline","source":"prnewswire.com","summary":"Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsight - prnewswire.com","headline":"Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOYTh2QUd3RVRsamgwaURHQ1ZkRU14WG1ZNGFEUE8xWUQzMEZ6YnlBUkFNeFdJMDhvSWh6QjF5cDQ2NjV3c1RoNnBOZHlTdW9kSHU3NkdtbldpRGhnYmZROGdkUmR5U1ZvMnB6b0ExMmJpUmEyU0NWTURNOE5MRldKQU5HdHdiQXJYXzZrSGMzUk9jODFsRkdaUkxqYy1iaWNPY29SV29la29vdmktSjZPVXJMUTREWkNfQy1OREhPZ3lBYWFON2RybUI2UWhIUkw3Ykk2dEx5WXFrUjNYTVVwNw?oc=5","date":"2022-01-20","type":"pipeline","source":"uktechnews.info","summary":"Engitix secures £40 million Series A investment co-led by Netherton Investments and Dompé farmaceutici S.P.A - uktechnews.info","headline":"Engitix secures £40 million Series A investment co-led by Netherton Investments and Dompé farmaceutici S.P.A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOdnVDM3BteWFtTzJ0V1o0N05DTmNZMzdGZWZvWGJlVldNSW5OMENWRU9fdHBySXNJYnJUWGF2cEQtMFk5NW5JN0JPOHl6ajlCSDF2M19jaTdsX3RJSnE5VWpFMmE3TS1vMHRtNjBxQk1sdFczbm9KUWFNMUdvTDNCUk9vTXBwamhWTTJOaGdBSjg0Q3NFRVI5TkdFMFV0QQ?oc=5","date":"2022-01-19","type":"deal","source":"Pharmafile","summary":"Engitix and Dompé collaboration for fibrosis and cancer AI drug discovery - Pharmafile","headline":"Engitix and Dompé collaboration for fibrosis and cancer AI drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMVZWU2hwVnlvcHFLaS1QLTg5UVJtc3NIRklYTHpqS2tWZTBvWUo5U3pnd0xyVGk2N1N0alkzM2RwQUFOeDdzRFA1M1E0VHpqY0R2NlBJUVhzbllmMzgxYlU3UmY1Q1dZOEhBREZEbzRIOGZENlBiNi1VbnZadXpvQ0RMVXgzYlBnZlJSUUdIWjd3TVppV01xLU1YS1hZTXJ1X3Vva1AtX2I1dlJzaFRaQjcyRUw1OFM4?oc=5","date":"2018-08-23","type":"regulatory","source":"upi.com","summary":"FDA approves first drug to treat rare corneal eye condition - upi.com","headline":"FDA approves first drug to treat rare corneal eye condition","sentiment":"positive"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":3,"phase_1":1,"marketed":3,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}